The Latest Cardiac and Vascular News
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Blackstone (NYSE: BX) and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the closing of the R&D funding component of the companies’ previously announced $2 billion strategic financing collaboration to accelerate the advancement of RNAi therapeutics. Under the terms of the agreement, Alnylam will receive up to […]
MORRISVILLE, N.C.–(BUSINESS WIRE)–Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today reported financial results for the second quarter 2020 and provided a business update. “The recently completed Phase 2 trial of patients with pulmonary hypertension and heart […]
WARRINGTON, Pa., Aug. 13, 2020 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (NASDAQ: WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, today reported financial results for the second quarter ended June 30, 2020 and provided […]
Novel technology defines new product category for accessible, cost-effective point-of-care magnetic resonance imaging. GUILFORD, Conn.–(BUSINESS WIRE)–Hyperfine Research, Inc. has received 510(k) clearance from the US FDA for its category-defining portable MRI technology, the Swoop™ Portable MR imaging device. Hyperfine’s Swoop™ system is a point-of-care MR imaging device that wheels directly to […]
VANCOUVER and MINNEAPOLIS, MN, Aug. 13, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), today provided a corporate update on progress towards its value creation strategies. Fred Colen, Chief Executive Officer of Neovasc, commented, “We are pleased to provide a corporate update to our investors as we have […]
SAN CARLOS, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) — BioCardia®, Inc. [NASDAQ: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today reported financial results and business highlights for the second quarter of 2020 and filed its quarterly report on Form 10-Q for the three and six months […]
Clinical programs advanced and expanded with strengthened cash position Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, N.J., Aug. 13, 2020 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not […]
On track to report TRILOGY 2 topline data on or about August 31, 2020 LAVAL, Québec, Aug. 13, 2020 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® […]
Key Highlights Osprey Medical has received European CE Marking approval for the 2nd generation DyeVert Power XT device Approval of DyeVert Power XT (for automatic injection) means the full coronary angiography market is now available to Osprey’s DyeVert franchise Device is expected to be a core product in the product portfolio […]
The first and only FDA-approved gadolinium-based contrast agent for multi-patient dosing with an FDA-cleared Transfer Spike in the MR suite. INDIANOLA, Pa.–(BUSINESS WIRE)–Please replace the release with the following corrected version due to multiple revisions. The updated release reads: FDA APPROVES GADAVIST® (GADOBUTROL) IMAGING BULK PACKAGE The first and only FDA-approved […]
